Company: TAK
Filing Date: 2025-07-30
Form Type: 6-K
Source: 0001395064-25-000120
Chunk: 21

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-07-30
Form: 6-K
Chunk 21
---
 from other components of equity  |     |                                              |         |     |         |        |     |                                                 |  397 |     |                            |       724 |     |                                              |         — |     |             |     |     |        |         — |
| Share-based compensation                   |     |                                              |         |     |         |        |     |                                                 |      |     |                            |         — |     |                                              |    17,084 |     |             |     |     |        |    17,084 |
| Exercise of share-based awards             |     |                                              |         |     |         |        |     |                                                 |      |     |                            |         — |     |                                              |         — |     |             |     |     |        |         — |
| Total transactions with owners             |     |                                              |       — |     |         |      — |     |                                                 |  397 |     |                            |       724 |     |                                              |  -188,901 |     |             |   — |     |        |  -188,901 |
| As of June 30, 2025                        |     |                                              | -61,197 |     |         | -6,075 |     |                                                 |    — |     |                            | 2,347,471 |     |                                              | 6,865,259 |     |             | 921 |     |        | 6,866,179 |

<div align='center'>19</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Three-month

Period Ended June 30, 2025 (Consolidated)

(5) Condensed Interim Consolidated Statements of Cash Flows

|                                                                                                                     |     | JPY (millions)                    
 Three-month Period Ended June 30, |     2024 |     |     |    2025 |
|:--------------------------------------------------------------------------------------------------------------------|:----|:----------------------------------|---------:|:----|:----|--------:|
| Cash flows from operating activities:                                                                               |     |                                   |          |     |     |         |
| Net profit for the period                                                                                           |     |                                   |   95,299 |     |     | 124,279 |
| Depreciation and amortization                                                                                       |     |                                   |  192,220 |     |     | 181,636 |
| Impair